Formulation and Characterization of Antigen-loaded PLGA Nanoparticles for Efficient Cross-priming of the Antigen

Young-Ran Lee1, Young-Hee Lee1, Sun-A Im1, Kyungjae Kim2 and Chong-Kil Lee1*

1College of Pharmacy, Chungbuk National University, Cheongju 361-763, 2College of Pharmacy, ShamYook University, Seoul 139-742, Korea

Background: Nanoparticles (NPs) prepared from biodegradable polymers, such as poly(D,L-lactic acid-co-glycolic acid) (PLGA), have been studied as vehicles for the delivery of antigens to phagocytes. This paper describes the preparation of antigen-loaded PLGA-NPs for efficient cross-priming.

Methods: NPs containing a similar amount of ovalbumin (OVA) but different sizes were produced using a micro-mixer-based W/O/W solvent evaporation procedure, and the efficiency of the NPs to induce the cross-presentation of OVA peptides were examined in dendritic cells (DCs). Cellular uptake and biodistribution studies were performed using fluorescein isothiocyanate (FITC)-loaded NPs in mice.

Results: The NPs in the range of 1.1 ∼ 1.4 μm in size were the most and almost equally efficient in inducing the cross-presentation of OVA peptides via H-2Kb molecules. Cellular uptake and biodistribution studies showed that opsonization of the NPs with mouse IgG greatly increased the percentage of FITC-positive cells in the spleen and lymph nodes. The major cell type of FITC-positive cells in the spleen was macrophages, whereas that of lymph nodes was DCs. Conclusion: These results show that IgG-opsonized PLGA-NPs with a mean size of 1.1 μm would be the choice of biodegradable carriers for the targeted-delivery of protein antigens for cross-priming in vivo.

INTRODUCTION

Nano- and microparticles prepared from biodegradable polymers, such as PLGA and poly(L-lactic acid) (PLG) have been studied extensively for the sustained delivery of therapeutic agents including DNA, proteins and low molecular weight pharmacological agents (1,2). Nano- and microparticles prepared from PLGA and PLG have also been studied as a vehicle to deliver encapsulated antigens to phagocytes (3-5). PLGA-microspheres have been shown to deliver antigens to APCs efficiently and generate Th1-type immune responses even against poor immunogens (6,7). Antigens encapsulated with PLGA were at least 100 times more effectively presented by MHC-I molecules on DCs compared to the soluble form of the antigens (8). One of the major advantages of encapsulation would also be the protection of the antigen or the drug from premature release and degradation (1).

Recent studies have shown that PLGA particle-mediated antigen delivery enhances and prolongs the MHC class I-restricted presentation of the exogenous antigens (cross-presentation) in DCs (5,9). The uptake of PLGA-particles by phagocytes is influenced by a range of factors, such as the size, surface properties and concentration in the medium (10-12). Particles between 3 ∼ 10 μm in size were preferentially internalized by APCs (13,14). Although many studies have reported on the uptake of PLGA particles by phagocytes, relatively little is known about the relationship between the particle size and cross-presentation-inducing ability of the particles. The in vivo specific targeting of PLGA-encapsulated antigens to professional APCs is essential for the efficient induction of antigen-specific CD8 T cell responses. Although neutrophils are the most aggressive phagocytic cells in the blood, they do not serve as professional APCs. Because...
professional APCs express receptors for the Fc region of IgG, opsonization of PLGA particles with IgG might be a way of preferentially targeting particles to professional APCs. In the present study, OVA-containing PLGA particles with different sizes but containing similar amounts of OVA were generated and the cross-presentation-inducing activities in DCs were compared. In addition, the effect of opsonizing the PLGA particles with IgG on the cellular uptake and biodistribution in mice was examined.

MATERIALS AND METHODS

Cells and cell culture

A T cell hybridoma, B3Z86/90,14 (B3Z), was kindly provided by Dr. Nilabh Shastri (University of California, Berkeley, CA) and T cell hybridomas, CD8 OVA1.3, were kindly provided by Dr. Clifford V. Harding (Case Western Reserve University, Cleveland, OH) (15,16). Bone marrow (BM)-derived DCs were generated from mouse bone marrow cells, as described previously (8). Briefly, BM cells obtained from the femurs of BALB/c mouse were cultured in a 6-well plate (5×10⁶/well) in a culture medium supplemented with 200 U/ml rmGM-CSF. At days 3 and 4 from the initiation of culture, the non-adherent cells were discarded by replacing the culture medium with fresh medium containing the cytokines after gentle shaking. The DCs were harvested by gentle pipetting at day 6.

Preparation of PLGA particles

Particles containing OVA were prepared, as described previously with minor modifications (12). Briefly, 400 μl of OVA (100 mg/ml) was added to 2 ml of ethyl acetate containing 200 mg of polylactic-co-glycolic acid (PLGA, Sigma-Aldrich). The mixture was then stirred at 20,000 rpm (Homogeniser, IKA, Japan) in the presence or absence of simultaneous sonication (Ultrasonic bath: 500 W, 30 kHz, BRANSON). After 3 min of emulsification, 8 ml of an aqueous solution of polyvinyl alcohol (PVA, 5%) was added to the w/o emulsion to form a w/o/w double emulsion, which was stirred for 5 min. To solidify the nanoparticles, the organic solvent was evaporated by stirring the double emulsion with 200 ml of an aqueous solution of 0.1% PVA at 500 rpm for 2 h. For the complete removal of ethyl acetate, the dispersion of nanoparticles was concentrated to approximately half the volume using a rotary evaporator at 40°C. The resulting nanoparticles were centrifuged at 3,000 rpm for 20 min, and washed twice with phosphate-buffered saline (PBS). The mean size of the particles was measured using a particle size analyzer (ELS-Z, Otsuka, Japan). The OVA concentration was determined using a micro-bicinchoninic acid assay kit (Pierce, Rockford, IL) after lysing the nanoparticles in a lysis buffer containing 0.1% SDS and 0.1 N NaOH. Nanoparticles containing both OVA and fluorescein isothiocyanate (FITC) were prepared by adding FITC (final, 5 mg/ml) to ethyl acetate along with PLGA (final, 5%). The surface morphology of the formulated NPs was visualized by scanning electron microscopy (LEO-1530, Carl Zeiss, Germany).

Opsonization with IgG

OVA-specific mouse IgG (mIgG) was attached covalently to the nanoparticles using (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) (EDC, Pierce, Rockford, IL, USA) as previously described (12). Briefly, 4.5 μg of EDC was added to a 360 μl mixture of 400 μg nanoparticles (as OVA concentration) and 400 μg mIgG. The reaction mixture was incubated for 2 h by tapping at room temperature. An excess linking reagent and soluble byproducts were separated by centrifugation at 15,000 rpm for 10 min, and the nanoparticles were washed three times with 1 ml PBS, pH 7.4.

MHC class I-restricted presentation assay

The DCs were added to a 96-well microtiter plate (1×10⁶/well) and were then added with the nanoparticles. The plate was incubated for 2 or 18 h at 37°C, washed twice with 300 μl/well of pre-warmed PBS and fixed with 100 μl/well of ice-cold 1.0% paraformaldehyde for 5 min at room temperature. The plate was then washed three times with 300 μl/well of PBS. Class I MHC-complexed OVA peptide quantities were assessed using LacZ T cell activation assays or by IL-2 secretion assays after culturing the paraformaldehyde-fixed DCs with B3Z cells (2×10³/well) for 4 h or with CD8 OVA1.3 cells (2×10³/well) for 18 h, as described previously (8,17).

In vitro release of OVA

Four milligrams of OVA-NPs were dispersed in 4 ml of PBS (pH 7.2) containing 0.02% sodium azide. The suspension was then aliquoted to a 500 μl/microfuge tube, and the microfuge tubes were kept at 37°C or 4°C. At the indicated days, the microfuge tubes were centrifuged at 15,000 rpm for 10 min, and the supernatants were transferred to new tubes. The supernatants were filtered through a membrane filter (pore size
Table I. Effects of the homogenization speed and sonication on the size and physicochemical properties of OVA-loaded nanospheres

| Homogenization speed (rpm) | Sonication | Average particle size (nm) | Polydispersity index | Zeta potential (mV) | OVA encapsulation efficiency (%) |
|---------------------------|------------|---------------------------|----------------------|---------------------|----------------------------------|
| 11,000                    | +          | 765.1                     | 0.435                | −4.47               | 24.8                             |
|                           | −          | 1,800.2                   | 0.440                | −5.36               | 23.0                             |
| 15,000                    | +          | 581.8                     | 0.286                | −4.04               | 24.0                             |
|                           | −          | 1,436.0                   | 0.180                | −5.06               | 25.0                             |
| 20,000                    | +          | 561.4                     | 0.250                | −3.10               | 24.8                             |
|                           | −          | 1,116.8                   | 0.027                | −4.16               | 22.0                             |

In vivo distribution of NP

C57BL/6 mice were injected i.p. with 100 μg of NPs containing both OVA and FITC. The mice were sacrificed 2 h later, and mononuclear cell suspensions were prepared from the spleens and lymph nodes (popliteal, inguinal, mesenteric, and axillary). The single cell suspensions were fixed with paraformaldehyde and analyzed for FITC-positive cells by flow cytometry, or stained with phycoerythrin-labeled anti-mouse CD11b, CD11c, or Gr-1 monoclonal antibodies (BD pharmin-gen, San Diego, CA), after blocking the FcR-binding anti-CD16/CD32 monoclonal antibody (clone 2.4G2), as described previously (18). Flow cytometry was performed on a FACS Cantor (Becton-Dickinson).

RESULTS

Formulation and characteristics of nano- and microparticles

Table I lists the different formulation conditions used to prepare nano- and microparticles along with their mean particle size, polydispersity index, zeta potential and protein loading efficiency. As expected, increasing the homogenization speed resulted in smaller sized NPs. The application of sonication energy (500 W, 30 kHz) during homogenizing of the two phases, the ethyl acetate phase containing PLGA and water phase containing OVA, further decreased the size of the resulting NPs. The mean OVA content was determined using a micro-bicinchoninic acid assay kit after lysing the NPs in a lysis buffer, and was 22.0 ∼ 24.8%. The surface morphology of the NPs was visualized by scanning electron microscopy, and Fig. 1A shows a representative image of the NPs with an average size of 1.1 μm. The stability of the NPs was examined by assessing the amount of soluble OVA released from the NP, Fig. 1B gives a representative experimental result, which was performed using the NPs with a mean size of 1.1 μm. The OVA entrapped within the NPs was not released from the NPs for at least one week from the NPs if the NPs were stored at 4°C.

Effect of particle size on cross-presentation

To examine the relationship between the NP size and cross-presentation-inducing activity, the NPs were incubated with BM-DCs for 2 h and the DCs were fixed with paraformaldehyde. The amounts of H-2Kb-OVA peptides complexes
on DCs were assessed using OVA-specific CD8 T cell hybridomas, B3Z cells, which express β-galactosidase in response to T cell receptor (TcR) stimulation. As shown in Fig. 2, DCs phagocytosed NPs in the range of 1.11–1.44 μm in size were almost equally efficient in cross-presenting OVA peptides via H-2Kb molecules. The cross-priming-inducing activity of NPs decreased dramatically when the mean size of the NPs was reduced to 0.56 μm. Therefore, NPs with the average size of 1.11 μm were chosen for the experiments described hereafter.

**Effect of opsonization on cross-presentation**

The NPs (average size, 1.11 μm) were opsonized with mouse IgG, and the amounts and time kinetics of OVA peptide presentation were examined in BM-DCs. In this experiment, the amounts of H-2Kb-OVA peptide complexes on DCs were assessed using OVA-specific CD8 T cell hybridomas, CD8 OVA1.3 cells, which express IL-2 in response to H-2Kb-OVA peptide (SIINFEKL) complexes. As shown in Fig. 3, DCs incubated with the NPs containing OVA (NP[OVA]) were much more efficient in cross-presenting OVA peptides than those incubated with soluble OVA. In particular, the DCs incubated with mouse IgG-opsonized NPs (mIgG-NP[OVA]) were much more potent in cross-presenting OVA peptides than those incubated with (NP[OVA]). Moreover, the duration of cross-presenting OVA peptides was also extended markedly in DCs phagocytosed mIgG-NP[OVA], The DCs phagocytosed mIgG-NP[OVA] could present H-2Kb-OVA peptide (SIINFEKL) complexes for 24 h, whereas the DCs incubated with saturation amounts of synthetic OVA peptide, SIINFEKL, could present H-2Kb-SIINFEKL complexes for only 6 h.

**In vivo distribution of NP**

Two hours after an intraperitoneal injection of a single dose of 100 μg of FITC-loaded NPs, biodistribution analysis was performed using mononuclear cells isolated from the spleens and lymph nodes. As shown in Fig. 4, the percentage of FITC-positive cells in the spleen and lymph node were increased dramatically when the mice were injected with mouse IgG-opsonized FITC-loaded NPs, compared to the mice injected with unopsonized FITC-loaded NPs. Most of the FITC-positive cells were in the spleen (approximately 20% in the spleen vs. approximately 0.8% in the lymph nodes). To examine the cell type that is positive for FITC, the mono-
nuclear cells isolated from the spleens and lymph nodes were stained with PE-conjugated anti-mouse CD11b, CD11c, or Gr-1 monoclonal antibodies. As shown in Fig. 5, macrophages were the major cell type of FITC-positive cells in the spleen, whereas DCs were the major type in the lymph nodes.

DISCUSSION

One of the main issues addressed in the present study is the elucidation of the optimal size of PLGA particles for the induction of the most potent cross-priming for the antigens entrapped inside the particles. Therefore, the present study developed methods to produce PLGA-NPs with various mean sizes. This method is based on the micromixer-based W/O/W solvent evaporation procedure but with a slight modification, such as adding sonication energy during the homogenization procedure. PLGA-NPs containing almost the same amount of ovalbumin (OVA) were generated but with different mean sizes. The efficiency of the NPs to induce cross-presentation of the OVA peptides were examined in DCs. The NPs in the range of 1.1~1.4 μm in size were the most potent and almost equally efficient in inducing the cross-presentation of OVA peptides via H-2Kb molecules in DCs. The size of the PLGA-NPs optimal for cross-priming is markedly smaller than the size of the PLGA-NPs that were reported by other researchers to be optimal for phagocytosis by APCs. It PLGA-NPs between 3~10 μm in size were optimal for uptake by APCs (13,14).

One of the unique features of PLGA-NPs is the sustained release of the entrapped antigens. In addition, encapsulation of the antigen with PLGA would be the protection of the antigen from rapid degradation in the body (1). Therefore, particles prepared from PLGA have been studied extensively for the sustained delivery of therapeutic agents including DNA, proteins and low molecular weight pharmacological agents used as vehicles to facilitate antigen delivery to phagocytes (1,2). Moreover, PLGA-NPs are easily conjugated with IgG. Coating the PLGA-NPs with mouse IgG is expected to decrease the uptake of NPs by neutrophils while increasing the uptake of NPs by Fcγ receptor (FcγR)-positive cells, such as DCs and macrophages. Therefore, IgG-opsonized OVA-containing PLGA NPs with a average size of 1.1 μm would be the best vehicle for delivering antigen to professional APCs in vivo. This hypothesis was confirmed by the experiments described in this manuscript. Throughout this study, IgG-opsonized OVA-containing PLGA-NPs were found to be the superior means for inducing the cross-presentation of OVA peptides in DCs.

The reason this study focused on the cross-presentation-inducing activities of the PLGA-NPs in the present study is that the importance of enhancing cross-presentation, which was first demonstrated in the generation of CTL responses to minor histocompatibility antigens (19), has now been demonstrated to be an essential mechanism for the generation of CTL responses against tumor cells, transplanted cells, bacteria and even viruses (20-23). The present study also showed that DCs phagocytosed IgG-opsonized OVA-containing PLGA-NPs can present OVA peptides for the most extended time periods, compared to any other means used in this study. In addition, IgG-opsonized OVA-containing PLGA-NPs were captured efficiently by professional APCs in the spleen and lymph nodes when injected intraperitoneally.

Overall, these results show that IgG-opsonized PLGA-NPs with a mean size of 1.1 μm would be the choice of biodegradable carriers for the targeted-delivery of protein antigens for cross-priming in vivo.
ACKNOWLEDGEMENTS

This study was supported by the research grant of the Chungbuk National University in 2009.

CONFLICT OF INTEREST

The authors declare no financial or commercial conflicts of interest.

REFERENCES

1. Bevan MJ: Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay, J Exp Med 143:1283-1288, 1976
2. Champion JA, Walker A, Mitragotri S: Role of particle size in phagocytosis of polymeric microspheres, Pharm Res 25:1518-1521, 2008
3. Elamanchili P, Diwan M, Gao M, Samuel J: Characterization of poly(D/L-lactic-co-glycolic acid)-based particulate system for enhanced delivery of antigens to dendritic cells, Vaccine 22:2400-2412, 2004
4. Gerelchuluun T, Lee YH, Lee YR, Im SA, Song S, Park JS, Han K, Kim K, Lee CK: Dendritic cells process antigens encapsulated in a biodegradable polymer, poly(D/L-lactic-co-glycolide), via an alternate class I MHC processing pathway, Arch Pharm Res 30:1440-1446, 2007
5. Harding CV, Song R: Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules, J Immunol 153:4925-4933, 1994
6. Heath WR, Carbone FR: Cross-presentation, dendritic cells, tolerance and immunity, Annu Rev Immunol 19:47-64, 2001
7. HuangAY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens, Science 284:961-965, 1994
8. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP: Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens, Adv Drug Deliv Rev 57:391-410, 2005
9. Johansen P, Men Y, Merkle HP, Gander B: Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination, Eur J Pharm Biopharm 50:129-146, 2000
10. Kattanen J, Sandenson S, Shastri N: Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens, Proc Natl Acad Sci U S A 89:6020-6024, 1992
11. Kochek P, Obermaier N, Gegovar M, Kos J, Krish J: Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody, J Control Release 120:18-26, 2007
12. Lee JK, Lee MK, Yun YP, Kim Y, Kim JS, Kim YS, Kim K, Han SS, Lee CK: Acmenanum purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells, Int Immunopharmacol 1:1275-1284, 2001
13. Lee YH, Lee YR, Kim KH, Im SA, Song S, Lee MK, Kim Y, Hong JT, Kim K, Lee CK: Baccaurin III, a synthetic precursor of taxol, enhances MHC-restricted antigen presentation in dendritic cells, Int Immunopharmacol 2011 [Epub ahead of print]
14. Lee YR, Yang IH, Lee YH, Im SA, Song S, Li H, Han K, Kim K, Eo SK, Lee CK: Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells, Blood 105:3951-3955, 2005
15. Mundargi RC, Babu VR, Rungawasamy V, Patel P, Aminabhavi TM: Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives, J Control Release 125:193-209, 2008
16. Newman KD, Sosnowski DL, Kwon GS, Samuel J: Delivery of MUC1 mucin peptide by Poly(D,L-lactide-co-glycolic acid) microspheres induces type 1 T helper immune responses, J Pharm Sci 87:1421-1427, 1998
17. Panyam J, Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue, Adv Drug Deliv Rev 55:329-347, 2003
18. Sahoo SK, Panyam J, Prabha S, Labhasetwar V: Residual polyvinyl alcohol associated with poly(D,L-lactide-co-glycolide) polyvinyl acetate coated in biodegradable nanoparticles affects their physical properties and cellular uptake, J Control Release 82:105-114, 2002
19. Shen H, Ackerman AL, Gody V, Giudini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM, Hanlon DJ: Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles, Immunology 117:78-88, 2006
20. Sigal LJ, Crotty S, Andino R, Rock KL: Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires a viral DNA sensor, Nature 437:765-770, 2005
21. Venkataprasad N, Coombes AG, Singh M, Rohde M, Wilkinson K, Hudecz F, Davis SS, Vordermeier HM: Induction of cellular immunity to mycobacterial antigen adsorbed on lamellar particles of lactide polymers, Vaccine 17:8181-8189, 1999
22. Waelder-Men Y, Groettrup M: PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines, Adv Drug Deliv Rev 57:475-482, 2005
23. Yewdell JW, Haeryfar SM: Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design, Annu Rev Immunol 23:651-682, 2005